

# Drug Utilization Review Board

(DUR Board)

Meeting – March 10, 2010 @ 6:00 p.m.

Oklahoma Health Care Authority

4545 N. Lincoln Suite 124

Oklahoma City, Oklahoma 73105

Oklahoma Health Care Authority Board Room

---

## AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. February 10, 2010 DUR Minutes – Vote
  - B. February 11, 2010 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Retrospective Drug Utilization Review for October 2009
  - B. Medication Coverage Activity Audit for February 2010
  - C. Help Desk Activity Audit for February 2010

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Update Anxiolytic Prior Authorization Category – See Appendix C.**
  - A. Utilization Review
  - B. Current Prior Authorization Criteria
  - C. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Twynsta™ – See Appendix D.**
  - A. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

7. **Action Item – Vote to Prior Authorize Pennsaid® – See Appendix E.**
  - A. Product Summary
  - B. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

8. **30 Day Notice to Prior Authorize Mozobil®, Nplate®, and Arcalyst® – See Appendix F.**
  - A. Mozobil® Product Information
  - B. Nplate® Product Information
  - C. Arcalyst® Product Information

Items to be presented by Dr. Chonlahan, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Xopenex® and Albuterol HFA Products – See Appendix G.**
  - A. Current Prior Authorization Criteria
  - B. Utilization Review
  - C. COP Recommendations

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

10. **FDA and DEA Updates – See Appendix H.**
  
11. **Future Business**
  - A. Annual Review of Smoking Cessation Products
  - B. Annual Review of Growth Hormones
  - C. FY09 Annual Review
  - D. New Product Reviews
  
12. **Adjournment**